Tiuri Kroese, MD, University Medical Center Utrecht, Utrecht, Netherlands, explains the results of a retrospective, multicenter study which investigated the the incidence and outcomes of patients with oligometastatic esophagogastric cancer. Out of 200 patients who were involved, 40% underwent local therapy alone, 20% underwent local therapy plus systemic therapy, and a further 25% underwent best supportive care. The study reported that patients who received local treatment plus systemic therapy achieved the best rates of overall survival and progression free survival, which was confirmed by multivariate analysis. In terms of incidence, approximately 20-25% of patients with metastatic esophagogastric cancer from the institutions involved had oligometastatic disease. This interview took place at the European Society for Radiotherapy and Oncology (ESTRO) 2022 annual congress in Copenhagen, Denmark, and online.
